Abstract
Purpose: To study the pharmacokinetics and biodistribution of novel polyethyleneglycol (PEG) surface-modified poly(rac-lactide) (PLA) nanocapsules (NCs) and to investigate the influence of PEG chain length and content.
Methods: The biodistribution and plasma clearance in mice of different NC formulations were studied with [3H]-PLA. PLA-PEG copolymers were used in NC preparations at different chain lengths (5 kDa and 20 kDa) and PEG contents (10% and 30% w/w of total polymer). In vitro and in vivo stability were also checked.
Results: Limited [3H]-PLA degradation was observed after incubation in mouse plasma for 1 h, probably because of to the large surface area and thin polymer wall. After injection into mice, NCs prepared with PLA-PEG copolymers showed an altered distribution compared to poloxamer-coated PLA NCs. An increased concentration in plasma was also observed for PLA-PEG NCs, even after 24 h. A dramatic difference in the pharmacokinetic parameters of PLA-PEG 45-20 30% NCs compared to poloxamer-coated NCs indicates that covalent attachment, longer PEG chain lengths, and higher densities are necessary to produce an increased half-life of NCs in vivo.
Conclusions: Covalently attached PEG on the surface of NCs substantially can reduce their clearance from the blood compartment and alter their biodistribution.
Similar content being viewed by others
REFERENCES
S. Stolnik, L. Illum, and S. S. Davis. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 16:195-214 (1995).
D. D. Lasic. Novel applications of liposomes. Trends Biotechnol. 16:307-321 (1998).
P. D. Scholes, A. G. A. Coombes, M. C. Davies, L. Illum, and S. S. Davis. Particle engineering of biodegradable colloids for site-specific drug delivery. In K. Park (ed.), Controlled Drug Delivery: Challenges and Strategies, ACS, Washington, 1997, pp.73-106.
S. Stolnik, S. E. Dunn, M. C. Garnett, M. C. Davies, A. G. A. Coombes, D. C. Taylor, M. P. Irving, S. C. Purkiss, T. F. Tadros, S. S. Davis, and L. Illum. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm. Res. 11:1800-1808 (1994).
S. E. Dunn, A. G. A. Coombes, M. C. Garnett, S. S. Davis, M. C. Davies, and L. Illum. In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface-modified by poloxamer and poloxamine copolymers. J Control. Release 44:65-76 (1997).
M. J. Newmann, M. Balusubramanian, and C. W. Tood. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 32:199-223 (1998).
T. Yamaoka, Y. Tabata, and Y. Ikada. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:601-606 (1994).
R. Gref, Y. Minamitake, M. T. Peracchia, V. Trubetskoy, V. Torchilin, and R. Langer. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603 (1994).
R. Gref, A. Domb, P. Quellec, T. Blunk, R. H. Müller, J. M. Verbavatz, and R. Langer. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 16:215-233 (1995).
T. Verrecchia, G. Spenlehauer, D.V. Bazile, A. Murry-Brelier, Y. Archimbaud, and M. Veillard. Non-stealth (poly(lactic/albumin)) and stealth (poly(lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers. J. Control. Release 36:49-61 (1995).
F. Liu and D. Liu. Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm. Res. 12:1060-1064 (1995).
T. Takino, K. Konishi, Y. Takakura, and M. Hashida. Long circulating emulsion carrier systems for highly lipophilic drugs. Biol. Pharm. Bull. 17:121-125 (1994).
P. Legrand, G. Barratt, V. Mosqueira, H. Fessi, and J. P. Devissaguet. Polymeric nanocapsules as drug delivery systems: a review. S.T.P. Pharma Sci. 9:411-418 (1999).
F. Fawaz, F. Bonini, M. Guyot, A. M. Lagueny, H. Fessi, and J. P. Devissaguet. Disposition and protective effect against irritation after intravenous and rectal administration of indomethacin loaded nanocapsules in rabbits. Int. J. Pharm. 133:107-115 (1996).
V. Lenaerts, A. Labib, F. Chouinard, J. Rousseau, H. Ali, and J. van Lier. Nanocapsules with a reduced liver uptake: targeting of phthalocyanines to EMT-6 mouse mammary tumour in vivo. Eur. J. Pharm. Biopharm. 41:38-43 (1995).
V. C. F. Mosqueira, P. Legrand, R. Gref, B. Heurtault, M. Appel, and G. Barratt. Interactions between a macrophage cell line (J774A1) and surface-modified poly(D,L-lactide) nanocapsules bearing poly(ethylene glycol). J. Drug Target. 7:65-78 (1999).
V.C.F. Mosqueira, P. Legrand, A. Gulik, O. Bourdon, R. Gref, D. Labarre, and G. Barratt. Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials, in press.
P. Quellec, R. Gref,, L. Perrin, E. Dellacherie, F. Sommer, Y. M Verbavatz, and M. J. Alonso. Protein encapsulation within polyethylene glycol-coated nanospheres I. Physicochemical characterization. J. Biomed. Mater. Res. 42:45-54 (1998).
H. Fessi, F. Puisieux, J. P. Devissaguet, N. Ammoury, and S. Benita. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55:R1-R4 (1989).
I. Dos Santos, J. L. Morgat, and M. Vert. Hydrogen isotope exchange as a mean of labeling lactides. J. Label. Compd. Radiopharm. 41:1005-1015 (1998).
C. S. Auletta. Acute, subchronic and chronic toxicology. In M..J. Derelanko and M. A. Hollinger (eds.), CRC Handbook of Toxicology, CRC Press, Boca Raton, 1995, pp. 51-103.
M. Vert, S. Li, and H. Garreau. More about the degradation of (LA/GA) derived matrices in aqueous media. J. Control. Release 16:15-26 (1991).
M. Vert, S. M. Li, G. Spenlehauer, and P. Guerin. Bioresorbability and biocompatibility of aliphatic polyesthers. J. Mater. Sci. Mater Med. 3:432-446 (1992).
F. B. Landry; D. V. Bazile, G. Spenlehauer, M. Veillard, and J. Kreuter. Peroral administration of 14C-poly(D,L-lactic acid) nanoparticles coated with human serum albumin or polyvinyl alcohol to guinea pigs. J. Drug Target. 6:293-307 (1998).
D. Bazile, C. Prud'Homme, M-T. Bassoulet, M. Marlard, G. Spenlehauer, and M. Veillard. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84:493-498 (1995).
C. D. Oja, S. C. Semple, A. Chonn, and P. R. Cullis. Influence of dose on liposome clearance: critical role of blood proteins. Biochim. Biophys. Acta 1281:31-37 (1996).
M. Vittaz, D. Bazile, G. Spenlehauer, T. Verrecchia, M. Veillard, F. Puisieux, and D. Labarre. Effect of PEO density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials 17:1575-1581 (1996).
V.C.F. Mosqueira, P. Legrand, H. Pinto-Alphandary, F. Puisieux, and G. Barratt. Poly(D,L-lactide nanocapsules prepared by a solvent displacement process: Influence of the composition on physicochemical and structural properties. J. Pharm. Sci. 89:614-626 (2000).
V. C. F. Mosqueira, P. Legrand, C. Bories, J.Ph. Devissaguet, and G. Barratt. Comparative pharmacokinetics and in-vivo efficacy of an intravenous formulation of halofantrine in long-circulating nanocapsules in Plasmodium berghei-infected mice. Proc. Inter. Symp. Control. Rel. Bioact. Mater. 27:490-491 (2000).
O. Bourdon, V. C. F. Mosqueira, P. Legrand, and J. Blais. A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells. J. Photochem. Photobiol. B. 55:164-171 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mosqueira, V.C.F., Legrand, P., Morgat, JL. et al. Biodistribution of Long-Circulating PEG-Grafted Nanocapsules in Mice: Effects of PEG Chain Length and Density. Pharm Res 18, 1411–1419 (2001). https://doi.org/10.1023/A:1012248721523
Issue Date:
DOI: https://doi.org/10.1023/A:1012248721523